Circadian Variation of Anti-Factor Xa in Hospitalized Trauma Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorThe University of Texas Health Science Center, Houston
About this trial
The purpose of this study is to determine whether a circadian rhythm exists in anti-FXa levels and AT3 activity in hospitalized trauma patients receiving low-molecular-weight heparin (LMWH) chemoprophylaxis
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Inpatient admission for acute traumatic injury ≥72 hours
Prescribed LMWH subcutaneous for VTE chemoprophylaxis
Disqualifiers
Pregnancy
Brain hemorrhage or non-survivable injury
Chronic Kidney disease ≥ 3b estimated Glomerular Filtration Rate (eGFR) less than 30 interferes with coagulation
Chronic liver failure
Trial population
The study will be conducted at HCA Houston Northwest Medical Center and will include adult trauma patients admitted to the Trauma ICU and Trauma Surgical Floor
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
40 Participants
are grouped into 1 trial groupGroup A: Hospitalized Trauma Patients Receiving LMWH Chemoprophylaxis
Trial outcomes
Primary outcomes
1
Change in anti-factor Xa (anti-FXa) levels
Time frame
4 hours after the 3rd LMWH dose (T0), then every 6 hours (T6, T12, T18)2
Change in Antithrombin III (AT3) activity
Time frame
4 hours after the 3rd LMWH dose (T0), then every 6 hours (T6, T12, T18)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
The University of Texas Health Science Center, Houston
Lead sponsor
Sigma Theta Tau International Grant; Jerold B. Katz Endowment Fund
Collaborator
Source ClinicalTrials.gov